Advanced Biomed Inc.
ADVB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ADVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADVB
Advanced Biomed Inc. (ADVB) is a pre-revenue biotechnology company developing microfluidic biochip-based automated devices for oncology precision medicine, with ongoing research in early cancer screening, diagnosis, and treatment selection.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Advanced Biomed Inc. (ADVB) is a pre-revenue biotechnology company developing microfluidic biochip-based automated devices for oncology precision medicine, with ongoing research in early cancer screening, diagnosis, and treatment selection.
- Advanced Biomed has not generated any product revenue and does not expect to until regulatory approvals are obtained [sec_mda · as of 2026-05-15].
- As of March 31, 2026, the company reported net income of $5,982 thousand, compared to a net loss of $2,557 thousand for the same period in 2025 [sec_mda · as of 2026-05-15].
- Cash and equivalents were $2.6 million as of March 31, 2026, with shareholders' equity of $4.1 million [latest reported financials].
- The company is developing three automated devices: A+Pre, AC-1000, and A+SCDrop, focused on microfluidic biochip technology for oncology [sec_mda · as of 2026-05-15].
- Advanced Biomed plans to expand into the U.S. and European markets, with site selection and personnel recruitment targeted for January 2026 [sec_mda · as of 2025-11-19].
What works
- The company reported a net income of $5,982 thousand for the nine months ended March 31, 2026, a significant improvement from a net loss of $2,557 thousand in the prior-year period [sec_mda · as of 2026-05-15].
- Working capital surplus increased to $9,101 thousand as of March 31, 2026, up from $3,143 thousand as of June 30, 2025 [sec_mda · as of 2026-05-15].
- Advanced Biomed is advancing three automated devices (A+Pre, AC-1000, A+SCDrop) using proprietary microfluidic biochip technology for oncology applications [sec_mda · as of 2026-05-15].
What to weigh
- The company has never generated revenue from product sales and does not expect to until it completes clinical development and obtains regulatory approvals [sec_mda · as of 2026-05-15].
- There is substantial doubt about the company's ability to continue as a going concern, as it depends on future financing and product commercialization [sec_mda · as of 2026-02-13].
- Cash of $2.6 million as of March 31, 2026 is limited, and the company may need additional funding to support operations and expansion plans [latest reported financials].
- Clinical data from trials conducted in China will not be used for U.S. product registration, requiring separate U.S.-based trials and regulatory processes [sec_mda · as of 2025-11-19].
From the filings
Quoted directly from source documents.
The company has not generated any product revenue and does not expect to until regulatory approvals are obtained.
“generated any revenue from the sale of products, and we do not expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.”
SEC MD&A · May 15, 2026
The company reported net income of $5,982 thousand for the nine months ended March 31, 2026.
“For the nine-month periods ended March 31, 2026 and 2025, the Company reported net income (loss) of 5,982 thousand and (2,557) thousand, respectively.”
SEC MD&A · May 15, 2026
There is substantial doubt about the company's ability to continue as a going concern.
“All of these factors raise substantial doubt about the ability of the Company to continue as a going concern.”
SEC MD&A · February 13, 2026
The company is developing three automated devices: A+Pre, AC-1000, and A+SCDrop.
“Our main activities through March 31, 2026 have been re-organizational and capital raising activities and the research and development of three automated devices A + Pre, AC-1000 and A + SCDrop.”
SEC MD&A · May 15, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as going concern due to reliance on future financing [sec_mda · as of 2026-02-13].
- No revenue history — Company has never generated product revenue and may not do so for years [sec_mda · as of 2026-05-15].
- Limited cash runway — Cash of $2.6M as of March 31, 2026 may be insufficient for planned operations and expansion [latest reported financials].
- Regulatory hurdles in US — Chinese clinical data cannot be used for US registration, requiring separate trials [sec_mda · as of 2025-11-19].
What to watch
- Progress on U.S. and European market expansion, including site selection and personnel recruitment targeted for January 2026 [sec_mda · as of 2025-11-19].
- Ability to secure additional financing to support ongoing R&D and working capital needs [sec_mda · as of 2026-02-13].
- Clinical development milestones for the three automated devices (A+Pre, AC-1000, A+SCDrop) [sec_mda · as of 2026-05-15].
- Regulatory filings and approvals for product candidates in the U.S. and Europe [sec_mda · as of 2026-05-15].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Advanced Biomed Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Advanced Biomed Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
62.3 months
D/E 0.16 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 20, 2026- % of float
- 1.3%
- Days to cover
- 0.0
- Shares short
- 13,424
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Advanced Biomed Inc.?
Advanced Biomed Inc. (ADVB) is a pre-revenue biotechnology company developing microfluidic biochip-based automated devices for oncology precision medicine, with ongoing research in early cancer screening, diagnosis, and treatment selection.
Who is the CEO of Advanced Biomed Inc.?
Mr. Xiaomin Chen Ph.D. is the chief executive officer of Advanced Biomed Inc. (ADVB).
Where is Advanced Biomed Inc. headquartered?
Advanced Biomed Inc. (ADVB) is headquartered in New York, NY, United States.
What therapeutic areas does Advanced Biomed Inc. focus on?
Advanced Biomed Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.